Baseline patient characteristics and efficacy outcomes
| Study | Treatment (dose) | Time end point measured (months) | Drug regimen | Mean number of injections/implants | n | Baseline BCVA | Age (years) | Disease duration (months) | Baseline CRT (µm) | Patients gaining ≥15 letters (%) | BCVA increase (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VIBRANT12 | Aflibercept 2q4 | 6 | 6×monthly doses | 5.7 | 91 | 58.6 | 67.0 | 1.4 | 559 | 53 | 17.0 (11.9)* |
| Laser | 6 | − | 90 | 57.7 | 63.9 | 1.4 | 554 | 27 | 6.9 (12.9)* | ||
| BRAVO† | Ranibizumab 0.5 mg | 6 | 6×monthly doses | 5.7 | 129 | 53.7 | 67.2 | 3.2 | 544‡ | 60 | 18.1 (13.2) |
| Sham injection | 6 | − | 131 | 55.0 | 65.1 | 3.5 | 488‡ | 29 | 7.3 (13.1) | ||
| Tan et al27 | Ranibizumab 0.5 mg | 12 | 6×monthly doses, then PRN | 8.1 | 15 | 39.5 | 69.6 | 4.1 | 616‡ | 53 | 12.5 (19.3) |
| Laser | 12 | − | 21 | 46.2 | 66.7 | 3.5 | 519‡ | 19 | –1.6 (18.2) | ||
| GENEVA14§ | Dexamethasone 0.7 mg implant | 6 | 1 implant at month 0 | 1.0 | 291 | 54.3 | 64.7 | 5.2 | 562 | 23 | 7.4 (7.6)§ |
| Sham procedure | 6 | − | 279 | 54.8 | 63.9 | 5.1 | 539 | 20 | 4.9 (7.5)§ | ||
| BRIGHTER† | Ranibizumab 0.5 mg | 6 | 3×monthly doses, then PRN | 4.8 | 142 | 58.9 | 63.9 | 3.4 | 554‡ | 50 | 16.3 (10.2) |
| Ranibizumab 0.5 mg+laser | 6 | 3×monthly doses, then PRN | 4.5 | 143 | 56.7 | 66.7 | 3.2 | 582‡ | 48 | 15.0 (11.8) | |
| Laser | − | 72 | 58.3 | 67.1 | 2.8 | 558‡ | 26 | 5.2 (14.7) | |||
| COMRADE-B† | Ranibizumab 0.5 mg | 6 | 3×monthly doses, then PRN | 4.9 | 124 | 57.9 | 65.6 | 2.0 | 537 | 61 | 17.0 (11.2) |
| Dexamethasone 0.7 mg implant | 6 | 1 implant at month 0 | 117 | 58.4 | 65.7 | 1.7 | 545 | 37 | 9.1 (12.5) | ||
| RABAMES22 | Laser | 6 | − | 10 | 59.0 | 68.8 | 5.0 | 571 | 20 | 2 (16.9) | |
| Ranibizumab 0.5 mg | 6 | 3×monthly doses | ∼3.0 | 10 | 58.5 | 64.2 | 5.1 | 584 | 70 | 17 (12.5) | |
| Laser+ranibizumab 0.5 mg | 6 | 3×monthly doses | ∼3.0 | 10 | 64.5 | 65.9 | 6.0 | 506 | 70 | 6 (9.3) | |
| Battaglia Parodi et al8 | Laser | 3 and 12 | 33 | 65.6 | NA | NA | NA | NA | 9.7 (13.2) | ||
| Control | 3 and 12 | 35 | 64.6 | NA | NA | NA | NA | 11.1 (13.2) |
Battaglia Parodi et al8 decimal data are converted into BCVA letters.
*SDs were not reported in the VIBRANT publication,12 but were provided by the authors of the study.
†Data for BRAVO, BRIGHTER, COMRADE-B is reported after patient-level data analysis.
‡Central foveal thickness.
§In GENEVA,14 baseline characteristics were not split between patients with CRVO and those with BRVO. BCVA letters gained from the NICE assessment file entitled ‘Evidence review: dexamethasone implants (Ozurdex) for macular oedema after retinal vein occlusion (2010)’. SE of the mean was graphically estimated.
2q4, 2 mg monthly; BCVA, best-corrected visual acuity (assessed in terms of Early Treatment Diabetic Retinopathy Study letters); BRVO, branch retinal vein occlusion; CRT, central retinal thickness; CRVO, central retinal vein occlusion; NA, not applicable; NICE, National Institute for Health and Care Excellence; PRN, pro re nata (as needed); RCT, randomised controlled trial.